Search Results - "Kwak, E. L."

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer by Blaszkowsky, L.S., Ryan, D.P., Szymonifka, J., Borger, D.R., Zhu, A.X., Clark, J.W., Kwak, E.L., Mamon, H.J., Allen, J.N., Vasudev, E., Shellito, P.C., Cusack, J.C., Berger, D.L., Hong, T.S.

“…To determine the maximal tolerated dose of erlotinib when added to 5-fluorouracil (5-FU) chemoradiation and bevacizumab and safety and efficacy of this…”
Get full text

The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene by Torti, S V, Kwak, E L, Miller, S C, Miller, L L, Ringold, G M, Myambo, K B, Young, A P, Torti, F M

“…Ferritin is a ubiquitous and highly conserved protein which plays a major role in iron homeostasis. We have identified and sequenced a full-length cDNA for…”
Get full text

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors by Haber, D A, Bell, D W, Sordella, R, Kwak, E L, Godin-Heymann, N, Sharma, S V, Lynch, T J, Settleman, J

“…Somatic mutations within the kinase domain of the epidermal growth factor receptor (EGFR) are present in approximately 10% of non-small-cell lung cancer…”
Get full text

Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 by Kwak, E. L., Camidge, D. R., Clark, J., Shapiro, G. I., Maki, R. G., Ratain, M. J., Solomon, B., Bang, Y., Ou, S., Salgia, R.

“…Abstract only 3509 Background: PF-02341066 (PF) is a selective, ATP-competitive, small molecule oral inhibitor of the c-Met/HGFR and ALK receptor tyrosine…”
Get full text

Role for NF-κB in the Regulation of Ferritin H by Tumor Necrosis Factor-α(∗) by Kwak, Eunice L., Larochelle, Denis A., Beaumont, Carole, Torti, Suzy V., Torti, Frank M.

“…Ferritin is a ubiquitously distributed iron-binding protein that plays a key role in cellular iron homeostasis. It is composed of two subunits, termed H (heavy…”
Get full text

Murine ferritin heavy chain: isolation and characterization of a functional gene by Kwak, E L, Torti, S V, Torti, F M

“…A mouse liver genomic library screened with a full-length cDNA encoding murine ferritin heavy chain (mFHC) [Torti et al., J. Biol. Chem. 263 (1988)…”
Get more information

In vitro translation products of Drosophila mitochondria are contaminated with newly synthesized bacterial proteins by Fleming, J E, Kwak, E L

“…A previous study reported in this journal suggested that in vitro synthesis of Drosophila mitochondrial polypeptides could be performed provided certain…”
Get more information

Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) by Desai, J., Hong, Y.S., Kim, J.E., Kim, T.W., Han, S.W., Bang, Y.-J., Chee, C.E., Heong, V.Y.M., McRee, A., Chow, L.Q., Kwak, E.L., Infante, J.R., Wallin, J., Thakur, M. Das, Mwawasi, G., Foster, P., Cha, E., Bendell, J.C.

Get full text

PhaseI/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer by BLASZKOWSKY, L. S, RYAN, D. P, SHELLITO, P. C, CUSACK, J. C, BERGER, D. L, HONG, T. S, SZYMONIFKA, J, BORGER, D. R, ZHU, A. X, CLARK, J. W, KWAK, E. L, MAMON, H. J, ALLEN, J. N, VASUDEV, E

Get full text

Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma by Chi, A. S., Kwak, E. L., Clark, J. W., Wang, D. L., Louis, D. N., Iafrate, A. J., Batchelor, T.

“…Abstract only…”
Get full text

Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) by Bang, Y., Kwak, E. L., Shaw, A. T., Camidge, D. R., Iafrate, A. J., Maki, R. G., Solomon, B. J., Ou, S. I., Salgia, R., Clark, J. W.

“…Abstract only 3 Background: PF-02341066 (PF-1066) is a selective, ATP-competitive, small molecule, orally bioavailable inhibitor of the ALK and MET/HGF…”
Get full text

Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors by Gandhi, L., Bahleda, R., Cleary, J. M., Hollebecque, A., Kwak, E. L., Pandya, S., Tolaney, S., Abbas, R., Ananthakrishnan, R., Berkenblit, A., Boni, J., Clancy, J., Turnbull, K. W., VoVan, M., Shapiro, G., Soria, J.

“…Abstract only…”
Get full text

A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report by Cho, D. C., Heath, E. I., Cleary, J. M., Kwak, E. L., Gandhi, L., Lawrence, D. P., Zack, C., Teofilovici, F., Bradley, R., Karol, M. D., Shapiro, G., LoRusso, P.

“…Abstract only…”
Get full text

Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification by Lennerz, J. K., Kwak, E. L., Michael, M., Fox, S. B., Ackerman, A., Bergethon, K., Lauwers, G. Y., Christensen, J. G., Wilner, K. D., Haber, D. A., Salgia, R., Bang, Y., Clark, J. W., Solomon, B. J., Iafrate, A. J.

“…Abstract only…”
Get full text

Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors by Shapiro, G., LoRusso, P., Kwak, E. L., Cleary, J. M., Musib, L., Jones, C., de Crespigny, A., Belvin, M., McKenzie, M., Gates, M. R., Chan, I. T., Bendell, J. C.

“…Abstract only…”
Get full text

Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC) by Blaszkowsky, L. S., Abrams, T. A., Miksad, R. A., Zheng, H., Meyerhardt, J. A., Schrag, D., Kwak, E. L., Fuchs, C., Ryan, D. P., Zhu, A. X.

“…Abstract only…”
Get full text

Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors by Shapiro, G., Kwak, E. L., Dezube, B. J., Lawrence, D. P., Cleary, J. M., Lewis, S., Squires, M., Lock, V., Lyons, J. F., Yule, M.

“…Abstract only…”
Get full text

A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors by Tolcher, A. W., Mikulski, S. M., Messersmith, W. A., Kwak, E. L., Gibbon, D., Boylan, J., Xu, Z. X., DeMario, M., Wheler, J. J.

“…Abstract only…”
Get full text

Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer by Shaw, A. T., Yeap, B., Costa, D. B., Solomon, B. J., Kwak, E. L., Nguyen, A. T., Bergethon, K., Engelman, J. A., Iafrate, A. J.

“…Abstract only…”
Get full text

Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients by Tan, W., Wilner, K. D., Bang, Y., Kwak, E. L., Maki, R. G., Camidge, D. R., Solomon, B. J., Ou, S. I., Salgia, R., Clark, J. W.

“…Abstract only…”
Get full text